Reported Earnings • Aug 09
First quarter 2027 earnings released: EPS: JP¥43.15 (vs JP¥44.90 in 1Q 2026) First quarter 2027 results: EPS: JP¥43.15 (down from JP¥44.90 in 1Q 2026). Revenue: JP¥121.9b (up 21% from 1Q 2026). Net income: JP¥4.19b (down 3.9% from 1Q 2026). Profit margin: 3.4% (down from 4.3% in 1Q 2026). The decrease in margin was driven by higher expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Declared Dividend • Jul 26
Final dividend of JP¥80.00 announced Shareholders will receive a dividend of JP¥80.00. Ex-date: 29th September 2026 Payment date: 2nd December 2026 Dividend yield will be 461%, which is higher than the industry average of 6.1%. Sustainability & Growth Dividend is covered by earnings (45% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 6.2% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 25% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Board Change • Jun 04
High number of new directors Managing Executive Officer, CHRO, CCO & Director Ryo Kawamura was the last director to join the board, commencing their role in 2025. Announcement • May 13
UBE Corporation, Annual General Meeting, Jun 25, 2026 UBE Corporation, Annual General Meeting, Jun 25, 2026. Announcement • Jan 16
UBE Corporation Announces Restructuring of Domestic Production System in Cement-Related Business UBE Cement Corporation announced that, at the Board of Directors meeting, MUCC resolved to cease cement production at Kyushu Plant Kanda District 2 by around the end of March 2027 and to transform the district into a recycling promotion base specializing in various types of waste treatment, as described below. The business environment for the cement industry continues to face pressures from declining domestic demand and reduced profitability in export markets. Against this backdrop, MUCC is advancing initiatives to strengthen profitability and improve asset efficiency, aiming to achieve sustainable growth and enhance corporate value over the medium to long term. Meanwhile, as MUCC seeks to achieve carbon neutrality by 2050, a key effort is to improve its thermal energy substitution rate. In particular, MUCC considers it essential to expand the volume of waste treatment for thermal recycling at the Kyushu Plant, which has one of the leading cement production capacities in Japan, and to achieve a thermal energy substitution rate of 50% or more for MUCC as a whole. Under these circumstances, in order to establish an optimal operation system and strengthen the competitiveness of its cement business, MUCC will cease cement production at Kyushu Plant Kanda District 2 by around the end of March 2027 and consolidate operations at Kyushu Plant Kanda District 1, thereby improving the efficiency of production facilities across the entire Kyushu Plant. In addition, to maximize the use of its technologies and further improve the waste treatment substitution rate, MUCC will develop Kyushu Plant Kanda District 2 as a recycling promotion base, utilizing existing facilities for crushing and packing waste plastics and removing chlorine and foreign materials. MUCC will steadily execute these measures to further enhance corporate value and help build a sustainable society. Announcement • Apr 02
UBE Corporation (TSE:4208) completed the acquisition of Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for approximately €500 million. UBE Corporation (TSE:4208) signed a contract to acquire Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for an enterprise value of €460 million on October 3, 2024. For the last twelve months period ending September 30, 2024, Urethane Systems Business of LANXESS reported total revenue of €265 million and EBITDA of €50 million. The acquisition price is expected to be confirmed based on the price adjustment indicated in the stock purchase agreement. The acquisition will be financed through cash on hand and interest-bearing debt. The Urethane Systems business comprises 5 manufacturing sites globally as well as application laboratories in the USA, Europe and China. UBE Corporation will take over all operations from LANXESS with a total of around 400 employees. LANXESS will use the proceeds to reduce its net debt. The transaction is subject to the approval of the relevant authorities including regulatory approval. The transaction is expected to close in the first half of 2025. Nomura Holding America, Inc. acted as financial advisor to UBE Corporation. Matthias Töke, Katharina Spenner LL.M., Joachim Fröhlich LL.M., Katharina Weiner, Daniel Bork, Christoph Becker, Ariane Schaaf, Simone (Bach) Rieken LL.M., Johannes M. Baumann, LL.M., Christian Atzler, Christian Vocke, Richard Raoul Stefanink, Patrick H. Wilkening, Markus Hecht, Christian Reichel and Nicolas Kredel LL.M. of Baker & Mckenzie Partnerschaft Von Rechtsanwälten Wirtschaftsprüfern,Steuerberatern Und Solicitors acted as legal advisor to UBE Corporation. Masahiro Inaba, Byron Frost and Tetsuo Tsujimoto of Baker & McKenzie (Gaikokuho Joint Enterprise) acted as legal advisor to UBE Corporation.
UBE Corporation (TSE:4208) completed the acquisition of Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for approximately €500 million on April 1, 2025. All relevant antitrust authorities had granted the necessary approvals for the transaction Announcement • Mar 01
UBE Corporation to Report Fiscal Year 2025 Results on May 12, 2025 UBE Corporation announced that they will report fiscal year 2025 results on May 12, 2025 Reported Earnings • Nov 10
Second quarter 2025 earnings released: JP¥46.20 loss per share (vs JP¥55.26 profit in 2Q 2024) Second quarter 2025 results: JP¥46.20 loss per share (down from JP¥55.26 profit in 2Q 2024). Revenue: JP¥127.7b (up 17% from 2Q 2024). Net loss: JP¥4.49b (down 184% from profit in 2Q 2024). Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Buy Or Sell Opportunity • Nov 10
Now 25% undervalued after recent price drop Over the last 90 days, the stock has fallen 7.8% to €14.20. The fair value is estimated to be €19.01, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last 3 years. Earnings per share has declined by 15%. For the next 3 years, revenue is forecast to grow by 5.0% per annum. Earnings are also forecast to grow by 14% per annum over the same time period. Announcement • Oct 31
UBE Corporation Revises Earnings Forecast for the First Half of Fiscal Year Ending March 31, 2025 UBE Corporation revised earnings forecast for the First Half of fiscal year ending March 31, 2025. For the period,the company expected net sales of JPY 243,000 Million operating profit of JPY 6,000 Million and profit attributable to owners of parent of JPY 300 million or JPY 3.09 per basic share as compared to previous guidance of net sales of JPY 238,000 Million operating profit of JPY 7,500 Million and profit attributable to owners of parent of JPY 8,000 million or JPY 82.41 per basic share. Reasons for the Revision: Net sales are expected to exceed the previous forecast due to an increase in the selling price of elastomers as a result of rising raw material prices, despite sluggish sales of certain products in the Specialty Products Segment. Operating profit is projected to be lower than the previous forecast due to the impact of the lower of cost or market method on caprolactam, nylon polymers, and other products, in the Polymers & Chemicals Segment. Ordinary profit and profit attributable to owners of parent are expected to be significantly lower than previously forecast due to the posting of a share of loss of entities accounted for using equity method following the dissolution of LOTTE UBE SYNTHETIC RUBBER SDN. BHD., an equity method affiliate. Buy Or Sell Opportunity • Sep 27
Now 21% undervalued Over the last 90 days, the stock has risen 2.5% to €16.70. The fair value is estimated to be €21.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 14% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 5.4% per annum. Earnings are also forecast to grow by 7.6% per annum over the same time period. Upcoming Dividend • Sep 20
Upcoming dividend of JP¥55.00 per share Eligible shareholders must have bought the stock before 27 September 2024. Payment date: 04 December 2024. Payout ratio is a comfortable 34% but the company is paying out more than the cash it is generating. Trailing yield: 4.1%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.0%). Reported Earnings • Aug 06
First quarter 2025 earnings released: EPS: JP¥49.49 (vs JP¥37.67 in 1Q 2024) First quarter 2025 results: EPS: JP¥49.49 (up from JP¥37.67 in 1Q 2024). Revenue: JP¥115.4b (up 5.6% from 1Q 2024). Net income: JP¥4.80b (up 31% from 1Q 2024). Profit margin: 4.2% (up from 3.3% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €13.40, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 12x in the Chemicals industry in Germany. Total loss to shareholders of 8.3% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €9.66 per share. Declared Dividend • Jul 11
Final dividend of JP¥55.00 announced Shareholders will receive a dividend of JP¥55.00. Ex-date: 27th September 2024 Payment date: 4th December 2024 Dividend yield will be 352%, which is higher than the industry average of 6.1%. Sustainability & Growth Dividend is well covered by both earnings (35% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 8.2% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 28% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Jun 26
Full year 2024 earnings released: EPS: JP¥299 (vs JP¥72.25 loss in FY 2023) Full year 2024 results: EPS: JP¥299 (up from JP¥72.25 loss in FY 2023). Revenue: JP¥468.2b (down 5.4% from FY 2023). Net income: JP¥29.0b (up JP¥36.0b from FY 2023). Profit margin: 6.2% (up from net loss in FY 2023). The move to profitability was driven by lower expenses. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Reported Earnings • May 16
Full year 2024 earnings released: EPS: JP¥299 (vs JP¥72.25 loss in FY 2023) Full year 2024 results: EPS: JP¥299 (up from JP¥72.25 loss in FY 2023). Revenue: JP¥468.2b (down 5.4% from FY 2023). Net income: JP¥29.0b (up JP¥36.0b from FY 2023). Profit margin: 6.2% (up from net loss in FY 2023). The move to profitability was driven by lower expenses. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Buy Or Sell Opportunity • May 09
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 12% to €17.40. The fair value is estimated to be €14.49, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has declined by 54%. For the next 3 years, revenue is forecast to grow by 4.9% per annum. Earnings are also forecast to grow by 19% per annum over the same time period. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥50.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 01 July 2024. Payout ratio is a comfortable 65% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (4.9%). Announcement • Mar 02
UBE Corporation to Report Fiscal Year 2024 Results on May 13, 2024 UBE Corporation announced that they will report fiscal year 2024 results on May 13, 2024 Announcement • Feb 08
UBE Corporation Announces Appointment of Hideo Tamada as Director, Effective April 1, 2024 UBE Corporation announced Hideo Tamada as Director from Representative Director Senior Managing Executive Officer, Effective from April 1, 2024. Reported Earnings • Feb 07
Third quarter 2024 earnings released: EPS: JP¥113 (vs JP¥8.39 loss in 3Q 2023) Third quarter 2024 results: EPS: JP¥113 (up from JP¥8.39 loss in 3Q 2023). Revenue: JP¥114.9b (down 7.1% from 3Q 2023). Net income: JP¥10.9b (up JP¥11.7b from 3Q 2023). Profit margin: 9.5% (up from net loss in 3Q 2023). The move to profitability was driven by lower expenses. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Buying Opportunity • Dec 13
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 11%. The fair value is estimated to be €17.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 8.6% over the last 3 years. Earnings per share has declined by 51%. For the next 3 years, revenue is forecast to grow by 4.7% per annum. Earnings is also forecast to grow by 28% per annum over the same time period. Reported Earnings • Nov 07
Second quarter 2024 earnings released: EPS: JP¥55.26 (vs JP¥62.67 loss in 2Q 2023) Second quarter 2024 results: EPS: JP¥55.26 (up from JP¥62.67 loss in 2Q 2023). Revenue: JP¥108.9b (down 15% from 2Q 2023). Net income: JP¥5.36b (up JP¥11.4b from 2Q 2023). Profit margin: 4.9% (up from net loss in 2Q 2023). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Upcoming Dividend • Sep 21
Upcoming dividend of JP¥50.00 per share at 3.7% yield Eligible shareholders must have bought the stock before 28 September 2023. Payment date: 04 December 2023. The company is not currently making a profit and is not cash flow positive. Trailing yield: 3.7%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (5.9%). Buying Opportunity • Sep 20
Now 20% undervalued Over the last 90 days, the stock is up 9.9%. The fair value is estimated to be €20.91, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.6% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Aug 09
First quarter 2024 earnings released: EPS: JP¥37.67 (vs JP¥59.25 in 1Q 2023) First quarter 2024 results: EPS: JP¥37.67 (down from JP¥59.25 in 1Q 2023). Revenue: JP¥109.2b (down 6.0% from 1Q 2023). Net income: JP¥3.66b (down 36% from 1Q 2023). Profit margin: 3.3% (down from 4.9% in 1Q 2023). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Reported Earnings • May 16
Full year 2023 earnings released: JP¥72.25 loss per share (vs JP¥249 profit in FY 2022) Full year 2023 results: JP¥72.25 loss per share (down from JP¥249 profit in FY 2022). Revenue: JP¥494.7b (down 25% from FY 2022). Net loss: JP¥7.01b (down 129% from profit in FY 2022). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥45.00 per share at 4.8% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 30 June 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 4.8%. Within top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.7%). Reported Earnings • Feb 05
Third quarter 2023 earnings released: JP¥8.39 loss per share (vs JP¥88.13 profit in 3Q 2022) Third quarter 2023 results: JP¥8.39 loss per share (down from JP¥88.13 profit in 3Q 2022). Revenue: JP¥123.6b (down 27% from 3Q 2022). Net loss: JP¥814.0m (down 110% from profit in 3Q 2022). Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 1.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 9% per year. Board Change • Jan 11
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Outside Director Takefumi Fukumizu was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Dec 21
UBE Corporation Announces Resignation of Tetsuro Higashi, Outside Director, Effective January 4, 2023 UBE Corporation has announced that an outside director of the company will resign effective January 4, 2023. Resigning Director: Tetsuro Higashi, Outside Director, Date of resignation: January 4, 2023, Reason for resignation: Difficulty in holding concurrent positions due to the appointment as the Chairman of Leading-edge Semiconductor Technology Center (LSTC). Reported Earnings • Nov 16
Second quarter 2023 earnings released: JP¥62.67 loss per share (vs JP¥48.60 profit in 2Q 2022) Second quarter 2023 results: JP¥62.67 loss per share (down from JP¥48.60 profit in 2Q 2022). Revenue: JP¥128.6b (down 20% from 2Q 2022). Net loss: JP¥6.08b (down 227% from profit in 2Q 2022). Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 06
Second quarter 2023 earnings released: JP¥62.67 loss per share (vs JP¥48.60 profit in 2Q 2022) Second quarter 2023 results: JP¥62.67 loss per share (down from JP¥48.60 profit in 2Q 2022). Revenue: JP¥128.6b (down 20% from 2Q 2022). Net loss: JP¥6.08b (down 227% from profit in 2Q 2022). Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Announcement • Nov 02
UBE Corporation Revises Earnings Guidance for the First Half Ended September 30, 2022 and Full Year Ending March 31, 2023 UBE Corporation revised earnings guidance for the first half ended September 30, 2022 and full year ending March 31, 2023. For the first half ended September 30, 2022, the company now expects net sales to be JPY 244.8 billion, operating profit to be JPY 8.5 billion, loss attributable to owners of parent to be JPY 0.3 billion or JPY 3.10 per share against previous forecast of net sales of JPY 261.0 billion, operating profit of JPY 10.0 billion, profit attributable to owners of parent of JPY 1.5 billion or JPY 15.49 per share.For the full year ending March 31, 2023, the company now expects net sales to be JPY 547.0 billion, operating profit to be JPY 29.0 billion, profit attributable to owners of parent to be JPY 2.0 billion or JPY 20.63 per share against previous forecast of net sales of JPY 557.0 billion, operating profit of JPY 32.0 billion, profit attributable to owners of parent of JPY 15.0 billion or JPY 154.88 per share. Announcement • Sep 27
Santen Inc. and UBE Corporation Receives FDA Approval for OMLONTI(R) (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension Santen Inc. and UBE Corporation (UBE) announced that the U.S. Food and Drug Administration (FDA) has approved OMLONTI (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. The approval date was September 22. OMLONTI is developed jointly by Santen and UBE. Omidenepag isopropyl, the active pharmaceutical ingredient in OMLONTI, developed by UBE, is a relatively selective prostaglandin EP2 receptor agonist, which increases aqueous humor drainage through the conventional (or trabecular) and uveoscleral outflow pathways, and the only product with this pharmacological action. OMLONTI was launched in Japan as Eybelis ophthalmic solution 0.002% in November 2018, and was filed for marketing approval in Asian countries in stages. The product was released in five countries and regions beginning in February 2021. OMLONTI was evaluated in three randomized and controlled clinical trials in subjects with open-angle glaucoma or ocular hypertension with average baseline IOP of 24-26 mm Hg. The double-masked treatment duration was three months in all three studies. The third study included a 9-month open-label treatment period following the 3-month double-masked treatment period. In the three studies, IOP reductions were observed for all treatment arms. In the OMLONTI arm, the reduction in IOP ranged from 5-7 mm Hg across all three studies. The corresponding reductions for the timolol and latanoprost arms were 5-7 mm Hg and 6-8 mm Hg, respectively. Glaucoma causes damage to the optic nerve resulting in visual field loss, and remains a leading cause of irreversible blindness worldwide. 2 Since the disease is generally progressive, early detection and treatment to control the progression are crucial, and lowering IOP is the most effective means of avoiding damage to the optic nerve. The estimated number of patients globally in 2020 was 76 million, and it is expected to increase to 95 million by 2030. 3 Primary open-angle glaucoma is the most common type of glaucoma. Ocular hypertension, which affects millions, can lead to glaucoma and vision loss if untreated. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥50.00 per share Eligible shareholders must have bought the stock before 29 September 2022. Payment date: 02 December 2022. Payout ratio is a comfortable 36% but the company is paying out more than the cash it is generating. Trailing yield: 4.9%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (6.1%). Reported Earnings • Aug 05
First quarter 2023 earnings released: EPS: JP¥59.25 (vs JP¥47.31 in 1Q 2022) First quarter 2023 results: EPS: JP¥59.25 (up from JP¥47.31 in 1Q 2022). Revenue: JP¥116.2b (down 21% from 1Q 2022). Net income: JP¥5.74b (up 21% from 1Q 2022). Profit margin: 4.9% (up from 3.3% in 1Q 2022). The increase in margin was driven by lower expenses. Over the next year, revenue is expected to shrink by 21% compared to a 3.9% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Jun 28
UBE Corp American Depositary Receipts - Unsponsored to Be Deleted from Other OTC UBE CORPORATION American Depositary Receipts - Unsponsored will be deleted from Other OTC effective June 28, 2022. The deletion is due to ADR /GDR Program Terminated. Reported Earnings • May 16
Full year 2022 earnings released: EPS: JP¥249 (vs JP¥227 in FY 2021) Full year 2022 results: EPS: JP¥249 (up from JP¥227 in FY 2021). Revenue: JP¥655.3b (up 6.7% from FY 2021). Net income: JP¥24.5b (up 6.8% from FY 2021). Profit margin: 3.7% (in line with FY 2021). Over the next year, revenue is expected to shrink by 29% compared to a 6.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year. Board Change • May 08
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 2 highly experienced directors. 4 independent directors (5 non-independent directors). Independent Outside Director Tadahiko Fukuhara was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Apr 07
UBE Corporation to Report Fiscal Year 2022 Results on May 12, 2022 UBE Corporation announced that they will report fiscal year 2022 results on May 12, 2022 Announcement • Feb 09
Ube Industries, Ltd. Announces Appointment of Makoto Koyama as Director, Effective April 1, 2022 Ube Industries, Ltd. has announced that the company's Board of Directors decided appointment of Makoto Koyama as director. Reason of Change is Change of management structure after April 1. Current Title is Representative Director, Senior Managing Executive Officer. Reported Earnings • Feb 04
Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Third quarter 2022 results: EPS: JP¥88.13 (up from JP¥86.03 in 3Q 2021). Revenue: JP¥169.9b (up 6.9% from 3Q 2021). Net income: JP¥8.55b (down 1.7% from 3Q 2021). Profit margin: 5.0% (down from 5.5% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 4.9%. Over the next year, revenue is expected to shrink by 28% compared to a 5.9% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 7% per year, which means it is performing significantly worse than earnings. Reported Earnings • Nov 03
Second quarter 2022 earnings released: EPS JP¥47.95 (vs JP¥15.85 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥153.3b (up 6.6% from 2Q 2021). Net income: JP¥4.77b (up 198% from 2Q 2021). Profit margin: 3.1% (up from 1.1% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 6% per year. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥45.00 per share Eligible shareholders must have bought the stock before 29 September 2021. Payment date: 02 December 2021. Trailing yield: 4.0%. Within top quartile of German dividend payers (3.2%). In line with average of industry peers (3.7%). Announcement • Aug 05
Ube Industries, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended September 2021 and Fiscal Year Ending March 31, 2022 Ube Industries, Ltd. provided consolidated earnings guidance for the six months ended September 2021 and fiscal year ending March 31, 2022. For the six months ended September 2021, the company expects net sales to be of JPY 270,000 million. Operating profit expected to be of JPY 13,500 million. Profit attributable to owners of parent expected to be of JPY 5,500 million. Net income per share expected to be of JPY 55.00.
For the Fiscal year ending March 31, 2022, the company expects net sales to be of JPY 570,000 million. Operating profit expected to be of JPY 37,000 million. Profit attributable to owners of parent expected to be of JPY 21,000 million. Net income per share expected to be of JPY 210.67. Reported Earnings • Aug 04
First quarter 2022 earnings released: EPS JP¥47.31 (vs JP¥13.16 loss in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥146.3b (up 7.5% from 1Q 2021). Net income: JP¥4.76b (up JP¥6.09b from 1Q 2021). Profit margin: 3.3% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Reported Earnings • May 13
Full year 2021 earnings released: EPS JP¥227 (vs JP¥227 in FY 2020) The company reported a mediocre full year result with weaker revenues, although earnings were flat and profit margins improved. Full year 2021 results: Revenue: JP¥613.9b (down 8.1% from FY 2020). Net income: JP¥22.9b (flat on FY 2020). Profit margin: 3.7% (up from 3.4% in FY 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Announcement • Apr 27
Ube Industries, Ltd. Revises Consolidated Earnings Guidance for the Full Year of the Fiscal Year Ended March 31, 2021 Ube Industries, Ltd. revised consolidated earnings guidance for the full year of the fiscal year ended March 31, 2021. For period, the company revised net sales of JPY 613.8 billion compared to JPY 592.0 billion provided previously, operating profit of JPY 25.9 billion compared to JPY 21.5 billion provided previously, profit attributable to owners of parent of JPY 22.9 billion compared to JPY 13.0 billion provided previously and net income per share of JPY 226.43 compared to JPY 128.54 provided previously. Upcoming Dividend • Mar 24
Upcoming dividend of JP¥45.00 per share Eligible shareholders must have bought the stock before 30 March 2021. Payment date: 29 June 2021. Trailing yield: 3.6%. Within top quartile of German dividend payers (3.3%). In line with average of industry peers (3.6%). 
